Home
Series of Journals
Literature
Latest literature
Popular literature
About us
Intro
Organizational structure
Editor in Chief
Copyright
Contact us
The title
The title
The keywords
The author
Wuhan University
Zhongnan Hospital of Wuhan University
Center for Evidence-Based and Translational Medicine of Wuhan University
Home
Results
The title
The title
The keywords
The author
A total of
13
result was found. Results that relate to
Pharmacoeconomic
Pharmacoeconomic evaluation of Huangkui capsule versus losartan potassium tablets in the treatment of IgA nephropathy
Published on
Chinese Journal of Pharmacoepidemiology
2023,32(1):02-09.
3820 times
2430 times
Liang-Wen GOU
Zhao-Ting GUO
Qiong LUO
Nan YANG
Ming HU
Huangkui capsule
Losartan potassium tablets
Chronic kidney disease
Pharmacoeconomic
s
Cost-utility analysis
Details
Bibliometric analysis of pharmacoeconomics evaluation research in China: based on the Web of Science database
Published on
Journal of Mathematical Medicine
2023,36(3):185-193.
2011 times
717 times
Yu-Liang GUI
Shi-Qiang XIANG
Pharmacoeconomic
s evaluation
CiteSpace
Bibliometrics
Visual analysis
Details
Cost-utility analysis of azacitidine versus decitabine in the treatment of myelodysplastic syndrome
Published on
Chinese Journal of Pharmacoepidemiology
2023,32(12):1371-1379.
1941 times
663 times
La-Ji DANZENG
Yong-Gong YANG
Si-Liang WANG
Meng-Ying LIU
Azacitidine
Decitabine
Myelodysplastic syndrome
Markov model
Cost-utility analysis
Pharmacoeconomic
s
Details
Cost-utility analysis of tislelizumab versus sorafenib as first-line treatment for advanced unresectable hepatocellular carcinoma
Published on
Frontiers in Pharmaceutical Sciences
2024,27(1):109-116.
1786 times
624 times
SU Zhan
CHE Jinhui
PEI Ruifeng
Hepatocellular carcinoma
Tislelizumab
Sorafenib
Partition survival model
Pharmacoeconomic
analysis
Details
Pharmacoeconomic study of Bailing capsules plus conventional therapy in treating diabetic kidney disease
Published on
Chinese Journal of Pharmacoepidemiology
2024,33(3):277-290.
1714 times
573 times
HE Yumei
LI Wei
ZHU He
HAN Sheng
Bailing capsules
Diabetic kidney disease
Meta-analysis
Cost- effectiveness analysis
Pharmacoeconomic
s
Details
Partitioned survival model of pharmacoeconomics evaluation of oncology therapy in R language
Published on
Journal of Mathematical Medicine
2024,37(4):240-251.
3681 times
883 times
LIU Jiayi
LI Wei
R language
Pharmacoeconomic
s evaluation
Health economic evaluation
Partitioned survival model
Oncology treating drugs
Details
Pharmacoeconomic evaluation of glucagon-like peptide-1 receptor agonist combined with metformin in the treatment of type 2 diabetes mellitus
Published on
Chinese Journal of Pharmacoepidemiology
2024,33(4):388-401.
2229 times
1132 times
YU Tian
LIU Shaohua
WEI Anhua
GUO Jieru
ZHANG Chengliang
LIU Dong
LIU Zhelong
Glucagon-like peptide-1 receptor agonist
Metformin
Type 2 diabetes mellitus
Cost-utility
Markov model
Pharmacoeconomic
s
Details
Pharmacoeconomic evaluation of aflibercept versus conbercept for the treatment of wet age-related macular degeneration
Published on
Frontiers in Pharmaceutical Sciences
2024,27(4):655-662.
2309 times
717 times
LIU Dan
ZHANG Bochao
ZHANG Jing
WANG Juan
YUAN Yi
GUI Lin
CHEN Li
Wet age-related macular degeneration
Aflibercept
Conbercept
Markov model
Pharmacoeconomic
analysis
Details
Cost-utiliy comparison of ranibizumab or aflibercept in the treatment of diabetic macular edema based on a Markov model
Published on
Frontiers in Pharmaceutical Sciences
2024,27(7):1155-1161.
2280 times
446 times
ZHU Yanxia
ZHOU Ruting
SHI Tianyan
Diabetic macular edema
Aflibercept
Ranibizumab
Pharmacoeconomic
s
Details
Pharmacoeconomic evaluation of fluticasone furoate/umeclidinium/ vilanterol powder for inhalation for the treatment of chronic obstructive pulmonary disease
Published on
Chinese Journal of Pharmacoepidemiology
2024,33(7):721-730.
2464 times
511 times
DING Xueru
LIU Huimin
HE Xiaodong
LI Hua
LI Zhihao
Fluticasone furoate/umeclidinium/vilanterol
Chronic obstructive pulmonary disease
Markov model
Cost-utility analysis
Pharmacoeconomic
Details
Cost-utility analysis of pembrolizumab combined with chemotherapy for advanced malignant pleural mesothelioma
Published on
Chinese Journal of Pharmacoepidemiology
2024,33(10):1107-1114.
1800 times
353 times
HU Yunjia
ZOU Keqing
HOU Yanhong
Pembrolizumab
Chemotherapy
Advanced malignant pleural mesothelioma
Partitioned survival model
Cost-utility analysis
Pharmacoeconomic
evaluation
Details
Pharmacoeconomic evaluation of third-line treatment of advanced non-small cell lung cancer with anlotinib
Published on
Frontiers in Pharmaceutical Sciences
2024,28(4):639-647.
1418 times
162 times
YUAN Wenjie
KANG Shuo
WANG Xiaohui
GONG Yuan
PAN Zhenhua
Anlotinib
Pharmacoeconomic
s
Non-small cell lung cancer
Cost-utility analysis
Details
Cost-effectiveness analysis of low-dose steriod combined with tacrolimus or cyclophosphamide in the treatment of adult idiopathic membranous nephropathy
Published on
Chinese Journal of Pharmacoepidemiology
2025,34(2):175-181.
1189 times
132 times
GUO Shanshan
GUO Li
LI Jiandong
ZHENG Xijie
CHEN Hang
Steroid
Tacrolimus
Idiopathic membranous nephropathy
Decision tree model
Pharmacoeconomic
s
Details
Wuhan University
Zhongnan Hospital of Wuhan University
Center for Evidence-Based and Translational Medicine of Wuhan University